300015 爱尔眼科
已收盘 06-11 15:00:00
资讯
新帖
简况
爱尔眼科:截至2025年底全球运营842家眼科机构
证券之星 · 06-11 08:58
爱尔眼科:截至2025年底全球运营842家眼科机构
爱尔眼科:我国近视呈高发化、低龄化、重度化趋势
证券之星 · 06-11 08:55
爱尔眼科:我国近视呈高发化、低龄化、重度化趋势
爱尔眼科:长期向头部集中是因为患者对医疗品质的需求是没有上限的
证券之星 · 06-11 08:51
爱尔眼科:长期向头部集中是因为患者对医疗品质的需求是没有上限的
爱尔眼科:眼科行业逻辑清晰,前途光明
证券之星 · 06-11 08:51
爱尔眼科:眼科行业逻辑清晰,前途光明
爱尔眼科:眼病治疗需求非常刚性
证券之星 · 06-11 08:51
爱尔眼科:眼病治疗需求非常刚性
爱尔眼科:专心致志提升自身,通过优质化、科技化、全球化,让更多人看清了视界
证券之星 · 06-11 08:51
爱尔眼科:专心致志提升自身,通过优质化、科技化、全球化,让更多人看清了视界
爱尔眼科:在合法合规的前提下,公司推动海内外技术双向赋能、成果互鉴
证券之星 · 06-11 08:51
爱尔眼科:在合法合规的前提下,公司推动海内外技术双向赋能、成果互鉴
爱尔眼科:公司各地分院深耕本地,逐步积累了患者口碑,持续扩大品牌护城河
证券之星 · 06-11 08:48
爱尔眼科:公司各地分院深耕本地,逐步积累了患者口碑,持续扩大品牌护城河
爱尔眼科:全民手机化、人口老龄化不断增加用眼负担
证券之星 · 06-11 08:48
爱尔眼科:全民手机化、人口老龄化不断增加用眼负担
爱尔眼科:公司持续拓展服务范围,精进诊疗能力,推动数字化落地,加快全球化发展
证券之星 · 06-11 08:48
爱尔眼科:公司持续拓展服务范围,精进诊疗能力,推动数字化落地,加快全球化发展
爱尔眼科:公司始终聚焦主业,落实战略规划,追求高质发展
证券之星 · 06-11 08:48
爱尔眼科:公司始终聚焦主业,落实战略规划,追求高质发展
全球化版图落子南美,爱尔眼科并购巴西眼科龙头
证券之星 · 06-10 21:15
全球化版图落子南美,爱尔眼科并购巴西眼科龙头
爱尔眼科宣布子公司拟斥资约6.96亿元收购巴西Clínicas do Brasil及Contact-Gel控股权
美股速递 · 06-10 19:24
爱尔眼科宣布子公司拟斥资约6.96亿元收购巴西Clínicas do Brasil及Contact-Gel控股权
爱尔眼科最新公告:拟通过全资子公司增资6.96亿元收购巴西眼科医疗服务集团控制权
证券之星 · 06-10 19:10
爱尔眼科最新公告:拟通过全资子公司增资6.96亿元收购巴西眼科医疗服务集团控制权
爱尔眼科:向历年来所有投资者赠送“明眸远观福利”
证券之星 · 06-05
爱尔眼科:向历年来所有投资者赠送“明眸远观福利”
爱尔眼科:2022年度7.17亿元、2023年度13.9亿元、2024年度14.87亿元、2025年度(含中期分红)16.7亿元
证券之星 · 06-03
爱尔眼科:2022年度7.17亿元、2023年度13.9亿元、2024年度14.87亿元、2025年度(含中期分红)16.7亿元
爱尔眼科:视网膜色素变性目前尚无法治愈
证券之星 · 06-02
爱尔眼科:视网膜色素变性目前尚无法治愈
爱尔眼科:赴港上市是公司全球化布局的重要一步
证券之星 · 06-01
爱尔眼科:赴港上市是公司全球化布局的重要一步
爱尔眼科冲刺“A+H”,海外并购能否续上增长故事
华尔街见闻 · 05-28
爱尔眼科冲刺“A+H”,海外并购能否续上增长故事
【新股IPO】爱尔眼科医院向港交所主板递交上市申请书 拟实现A+H上市
金吾财讯 · 05-27
【新股IPO】爱尔眼科医院向港交所主板递交上市申请书 拟实现A+H上市
加载更多
公司概况
公司名称:
爱尔眼科医院集团股份有限公司
所属行业:
卫生
上市日期:
2009-10-30
主营业务:
爱尔眼科医院集团股份有限公司的主营业务是各类眼科疾病诊疗、手术服务与医学验光配镜服务。公司的主要产品是屈光项目、白内障项目、眼前段项目、眼后段项目、视光服务项目。集团数字化多项成果获得行业及主管部门的高度认可。报告期内,“爱尔慢性眼病智能筛查一体化解决方案”获得全国人工智能应用创新大赛创新应用组二等奖;爱尔眼科“高真实感个性化眼科数字人底座开发与应用”项目成功入选湖南省“数字新基建”100个标志性项目名单;“爱尔眼科数字人及AierGPT”项目在第八届众智科学与工程国际会议(ICCSE2025)联合第十届人工智能与乐龄科技国际会议(ICAA2025)上荣获大会“最佳演示奖(BestDemoAward)”。同时,集团获湖南省发改委认定为“数字眼科湖南省工程研究中心”;主办中华医学会眼科学术大会眼科人工智能专题会,发布《爱尔眼科AI战略白皮书》,行业影响力显著提升。
发行价格:
28.00
{"stockData":{"symbol":"300015","market":"SZ","secType":"STK","nameCN":"爱尔眼科","latestPrice":8.41,"timestamp":1781161413000,"preClose":8.25,"halted":0,"volume":118717398,"delay":0,"changeRate":0.0194,"floatShares":7955000000,"shares":9325000000,"eps":0.3615,"marketStatus":"已收盘","change":0.16,"latestTime":"06-11 15:00:00","open":8.23,"high":8.61,"low":8.19,"amount":1008000000,"amplitude":0.0509,"askPrice":8.42,"askSize":2900,"bidPrice":8.41,"bidSize":4007,"shortable":0,"etf":0,"ttmEps":0.3615,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781227800000},"marketStatusCode":5,"adr":0,"adjPreClose":8.25,"symbolType":"stock","openAndCloseTimeList":[[1781141400000,1781148600000],[1781154000000,1781161200000]],"highLimit":9.08,"lowLimit":7.43,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":9325396670,"isCdr":false,"pbRate":3.34,"roa":"--","peRate":23.264177,"roe":"5.25%","epsLYR":0.3496,"committee":0.189085,"marketValue":78427000000,"turnoverRate":0.0149,"status":0,"floatMarketCap":66905000000},"requestUrl":"/m/hq/s/300015","defaultTab":"news","newsList":[{"id":"2642779804","title":"爱尔眼科:截至2025年底全球运营842家眼科机构","url":"https://stock-news.laohu8.com/highlight/detail?id=2642779804","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642779804?lang=zh_cn&edition=full","pubTime":"2026-06-11 08:58","pubTimestamp":1781139489,"startTime":"0","endTime":"0","summary":"证券之星消息,爱尔眼科06月11日在投资者关系平台上答复投资者关心的问题。公司早已开启全球化之旅,在欧洲、东南亚、美国、英国等地已进行布局,并于10日晚间发布公告收购巴西最大眼科医疗集团,正式进军拉丁美洲。截至2025年底,全球运营842家眼科机构,其中海外179家。按收入、门诊量、手术量等指标,公司居全球眼科医疗行业前列,通过深化“全球发展、本土运营、双向赋能”,海外占比有望大幅提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100004949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","LU1146622755.USD","BK0028","BK0196","BK0200","BK0236","LU1242518931.SGD","LU1242518857.USD","LU0979878070.USD","BK0077","BK0188","BK0012","300015","LU1820825898.SGD","BK0113","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642775504","title":"爱尔眼科:我国近视呈高发化、低龄化、重度化趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=2642775504","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642775504?lang=zh_cn&edition=full","pubTime":"2026-06-11 08:55","pubTimestamp":1781139309,"startTime":"0","endTime":"0","summary":"证券之星消息,爱尔眼科06月11日在投资者关系平台上答复投资者关心的问题。请问公司是否观察到了眼科疾病年轻化的明显趋势?随着屏幕化使用频率持续提升,居民日常用眼强度大幅增加,我国近视呈高发化、低龄化、重度化趋势,干眼症等与用眼强度相关眼病患病率不断上升。最好是医疗是预防,提醒大家注意用眼健康,经常上爱尔眼科网站了解眼健康知识,尽力防患于未然。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100004942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300015","BK0077","BK0188","LU0979878070.USD","BK0114","BK0200","BK0113","BK0028","BK0236","LU1820825898.SGD","LU1242518931.SGD","LU1146622755.USD","BK0196","BK0096","BK0012","LU1242518857.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642477586","title":"爱尔眼科:长期向头部集中是因为患者对医疗品质的需求是没有上限的","url":"https://stock-news.laohu8.com/highlight/detail?id=2642477586","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642477586?lang=zh_cn&edition=full","pubTime":"2026-06-11 08:51","pubTimestamp":1781139085,"startTime":"0","endTime":"0","summary":"证券之星消息,爱尔眼科06月11日在投资者关系平台上答复投资者关心的问题。“局部集中”,是普遍现象,各地头两三家医疗机构占据了大部分市场份额。“长期向头部集中”,是因为患者对医疗品质的需求是没有上限的,信息透明、交通便利、医保互通更加剧了这种长期趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100004893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","BK0113","LU1242518857.USD","LU1242518931.SGD","LU1146622755.USD","BK0114","BK0077","BK0012","LU1820825898.SGD","LU0979878070.USD","BK0236","300015","BK0188","BK0196","BK0200","BK0096","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642378477","title":"爱尔眼科:眼科行业逻辑清晰,前途光明","url":"https://stock-news.laohu8.com/highlight/detail?id=2642378477","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642378477?lang=zh_cn&edition=full","pubTime":"2026-06-11 08:51","pubTimestamp":1781139082,"startTime":"0","endTime":"0","summary":"证券之星消息,爱尔眼科06月11日在投资者关系平台上答复投资者关心的问题。茅台消愁,爱尔解忧。茅台可以在开心时举杯相庆,也可以在落寞时邀月对影。爱尔既为眼病患者雪中送炭,也为追求高质量视觉的人们锦上添花。毋庸讳言,眼科行业估值近年来下降较多,但长远看,这正是眼科行业凤凰涅槃创新突围的历史时刻。浓雾会放慢脚步,但挡不住大路,眼科行业逻辑清晰,前途光明。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100004890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0196","BK0200","BK0096","BK0188","LU1820825898.SGD","LU1146622755.USD","BK0028","BK0114","LU0979878070.USD","LU1242518857.USD","BK0113","BK0236","LU1242518931.SGD","300015","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642247737","title":"爱尔眼科:眼病治疗需求非常刚性","url":"https://stock-news.laohu8.com/highlight/detail?id=2642247737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642247737?lang=zh_cn&edition=full","pubTime":"2026-06-11 08:51","pubTimestamp":1781139081,"startTime":"0","endTime":"0","summary":"证券之星消息,爱尔眼科06月11日在投资者关系平台上答复投资者关心的问题。眼病本身不存在周期性,但患者的支付能力会受到经济周期的影响,因此,眼病治疗需求非常刚性,非基本需求具有一定的弹性,人们对眼健康和视觉质量的需求是长期客观存在的。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100004888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0200","BK0114","LU0979878070.USD","LU1242518857.USD","LU1146622755.USD","BK0236","BK0028","BK0012","BK0196","BK0113","LU1820825898.SGD","BK0077","BK0096","300015","LU1242518931.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642583477","title":"爱尔眼科:专心致志提升自身,通过优质化、科技化、全球化,让更多人看清了视界","url":"https://stock-news.laohu8.com/highlight/detail?id=2642583477","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642583477?lang=zh_cn&edition=full","pubTime":"2026-06-11 08:51","pubTimestamp":1781139080,"startTime":"0","endTime":"0","summary":"证券之星消息,爱尔眼科(300015)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问:公司当前动态市盈率仅16倍,处于近10年估值底部(历史分位<5%),请问管理层是否认为当前股价严重低估了公司的内在价值?爱尔眼科回复:谢谢关注。估值过高是不可持续的,估值过低也是不合理的。我们深信物质决定意识的基本原理,专心致志提升自身,通过优质化、科技化、全球化,让更多人看清了视界,也就让更多人看见了爱尔。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100004887.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0113","LU0979878070.USD","300015","LU1242518857.USD","BK0077","BK0188","LU1146622755.USD","LU1820825898.SGD","BK0196","BK0028","LU1242518931.SGD","BK0012","BK0114","BK0236","BK0096","BK0200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642322477","title":"爱尔眼科:在合法合规的前提下,公司推动海内外技术双向赋能、成果互鉴","url":"https://stock-news.laohu8.com/highlight/detail?id=2642322477","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642322477?lang=zh_cn&edition=full","pubTime":"2026-06-11 08:51","pubTimestamp":1781139078,"startTime":"0","endTime":"0","summary":"证券之星消息,爱尔眼科(300015)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问:公司此次港股上市募资还将用于眼科人工智能及技术生态系统开发,请问公司计划如何利用国际资源加速AI眼科技术的研发和全球推广?爱尔眼科回复:谢谢关注。在合法合规的前提下,公司推动海内外技术双向赋能、成果互鉴。公司已具备一定基础,未来大有可为。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100004884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU1820825898.SGD","BK0012","LU0979878070.USD","300015","BK0188","BK0077","BK0113","BK0114","BK0200","BK0236","LU1146622755.USD","BK0028","BK0096","LU1242518931.SGD","LU1242518857.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642477870","title":"爱尔眼科:公司各地分院深耕本地,逐步积累了患者口碑,持续扩大品牌护城河","url":"https://stock-news.laohu8.com/highlight/detail?id=2642477870","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642477870?lang=zh_cn&edition=full","pubTime":"2026-06-11 08:48","pubTimestamp":1781138895,"startTime":"0","endTime":"0","summary":"证券之星消息,爱尔眼科06月11日在投资者关系平台上答复投资者关心的问题。公司根据医疗国情和人口分布的实际情况,建立并持续完善分级连锁模式,上级医院为下级医院提供技术支持,下级医院为上级医院转诊疑难患者,将优质诊疗服务覆盖城乡县域。眼科医疗具备极强地域属性与就医粘性,公司各地分院深耕本地,逐步积累了患者口碑,持续扩大品牌护城河。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100004868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0028","BK0200","BK0077","BK0236","LU1242518857.USD","LU1820825898.SGD","LU1242518931.SGD","LU0979878070.USD","LU1146622755.USD","BK0096","BK0114","BK0188","BK0012","300015","BK0113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642477363","title":"爱尔眼科:全民手机化、人口老龄化不断增加用眼负担","url":"https://stock-news.laohu8.com/highlight/detail?id=2642477363","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642477363?lang=zh_cn&edition=full","pubTime":"2026-06-11 08:48","pubTimestamp":1781138894,"startTime":"0","endTime":"0","summary":"证券之星消息,爱尔眼科(300015)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问:面对未来眼科医疗行业的发展趋势和挑战,公司有哪些信心和底气实现长期高质量发展?爱尔眼科回复:谢谢关注。全民手机化、人口老龄化不断增加用眼负担,全年龄段眼健康需求持续扩容。公司以患者为中心,依托标准化质控和精细化管理,多维度夯实发展根基,不断扩大品牌影响力,保障持续高质量发展。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100004867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300015","BK0077","BK0188","LU0979878070.USD","BK0114","BK0200","BK0113","BK0028","BK0236","LU1820825898.SGD","LU1242518931.SGD","LU1146622755.USD","BK0196","BK0096","BK0012","LU1242518857.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642778714","title":"爱尔眼科:公司持续拓展服务范围,精进诊疗能力,推动数字化落地,加快全球化发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2642778714","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642778714?lang=zh_cn&edition=full","pubTime":"2026-06-11 08:48","pubTimestamp":1781138893,"startTime":"0","endTime":"0","summary":"证券之星消息,爱尔眼科(300015)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问:公司认为未来哪些因素将成为估值修复的核心催化剂?如何让大众认知到公司的潜能?爱尔眼科回复:谢谢关注。外部环境和政策预期对估值有一定影响,但估值修复最终还是靠公司持续展现出鼎故革新的朝气、科技驱动的锐气和众志成城的勇气。催化剂不是兴奋剂,变化隐含在细节中,公司持续拓展服务范围,精进诊疗能力,推动数字化落地,加快全球化发展,并加强与市场和大众的沟通。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100004866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0236","300015","BK0028","BK0114","BK0200","LU0979878070.USD","LU1242518857.USD","LU1820825898.SGD","LU1146622755.USD","BK0113","BK0012","BK0188","BK0077","LU1242518931.SGD","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642387477","title":"爱尔眼科:公司始终聚焦主业,落实战略规划,追求高质发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2642387477","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642387477?lang=zh_cn&edition=full","pubTime":"2026-06-11 08:48","pubTimestamp":1781138892,"startTime":"0","endTime":"0","summary":"证券之星消息,爱尔眼科(300015)06月11日在投资者关系平台上答复投资者关心的问题。投资者提问:请问管理层认为当前股价是否反映了公司的真实经营情况和未来发展潜力?爱尔眼科回复:谢谢关注。公司始终聚焦主业,落实战略规划,追求高质发展。“月亮走,我也走”,相信股价终将反映价值。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100004858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0113","BK0196","BK0236","BK0188","BK0012","LU1146622755.USD","300015","LU0979878070.USD","LU1820825898.SGD","LU1242518931.SGD","BK0096","BK0077","LU1242518857.USD","BK0200","BK0114","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642429147","title":"全球化版图落子南美,爱尔眼科并购巴西眼科龙头","url":"https://stock-news.laohu8.com/highlight/detail?id=2642429147","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642429147?lang=zh_cn&edition=full","pubTime":"2026-06-10 21:15","pubTimestamp":1781097342,"startTime":"0","endTime":"0","summary":"6月10日晚间,爱尔眼科发布公告称,拟通过境外全资子公司AIER Brazil,向SF 1125p Participaes Societárias S.A.增资认购其新增股份。此举意味着爱尔眼科将以巴西为“前哨”,在继欧洲、东南亚、北美之后,将全球化版图进一步延伸至南美洲。此前在H股招股书中,爱尔眼科明确表示募资用途之一是用于收购具备强大品牌声誉及卓越临床能力的海外眼科机构。此次收购巴西项目,将有效填补其在南美市场的布局空白,朝着构建世界级眼科医疗集团的目标迈出坚实一步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.stockstar.com/SS2026061000040700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0236","BK0077","LU1146622755.USD","BK0113","LU1242518857.USD","LU1820825898.SGD","159100","BK0188","BK0096","BK0012","LU1242518931.SGD","BK0196","LU0979878070.USD","BK0200","BK0114","300015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117275645","title":"爱尔眼科宣布子公司拟斥资约6.96亿元收购巴西Clínicas do Brasil及Contact-Gel控股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1117275645","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117275645?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:24","pubTimestamp":1781090658,"startTime":"0","endTime":"0","summary":"爱尔眼科集团股份有限公司发布公告称,其子公司计划以约6.96亿元人民币的总对价,收购巴西Clínicas do Brasil及Contact-Gel两家公司的控股权。此项交易旨在进一步拓展集团在拉丁美洲市场的业务布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0200","300015","BK0196","BK0236","LU0979878070.USD","BK0012","BK0114","BK0113","LU1820825898.SGD","BK0096","LU1146622755.USD","LU1242518857.USD","LU1242518931.SGD","BK0188","BK0077","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642428203","title":"爱尔眼科最新公告:拟通过全资子公司增资6.96亿元收购巴西眼科医疗服务集团控制权","url":"https://stock-news.laohu8.com/highlight/detail?id=2642428203","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642428203?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:10","pubTimestamp":1781089857,"startTime":"0","endTime":"0","summary":"爱尔眼科(300015.SZ)公告称,公司拟通过境外全资子公司AIERBrazil以现金方式向目标公司增资认购其新增股份,认购金额为5.30亿巴西雷亚尔(折合人民币约6.96亿元)。交易完成后,AIERBrazil将持有目标公司60.57%股权,间接控制巴西眼科医疗服务及视光相关业务集团。本次交易旨在推进全球化战略,拓展拉丁美洲业务布局。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000035959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0200","BK0114","LU0979878070.USD","LU1242518857.USD","LU1146622755.USD","BK0236","BK0028","BK0012","BK0196","BK0113","LU1820825898.SGD","159100","BK0077","BK0096","300015","LU1242518931.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641291194","title":"爱尔眼科:向历年来所有投资者赠送“明眸远观福利”","url":"https://stock-news.laohu8.com/highlight/detail?id=2641291194","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641291194?lang=zh_cn&edition=full","pubTime":"2026-06-05 12:27","pubTimestamp":1780633629,"startTime":"0","endTime":"0","summary":"证券之星消息,爱尔眼科(300015)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问:公司对于股东有屈光优惠政策吗?具体有哪些政策?爱尔眼科回复:谢谢关注。公司在上市十五周年之际,向历年来所有投资者赠送“明眸远观福利”。此项活动长期有效,具体参与方式请参阅公司于2024年10月31日发布的《关于举办“上市十五年,回馈投资者”活动的公告 》。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500018064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0200","BK0012","BK0077","BK0188","BK0113","LU0979878070.USD","LU1242518857.USD","LU1820825898.SGD","LU1242518931.SGD","BK0236","LU1146622755.USD","BK0196","300015","BK0096","BK0028","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640723259","title":"爱尔眼科:2022年度7.17亿元、2023年度13.9亿元、2024年度14.87亿元、2025年度(含中期分红)16.7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640723259","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640723259?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:03","pubTimestamp":1780473799,"startTime":"0","endTime":"0","summary":"证券之星消息,爱尔眼科(300015)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问:今年收入增长较好,怎么年度分红却下降呢?这与之前答复股民的提升分红相矛盾吧?爱尔眼科回复:公司近年来现金分红总额:2022年度7.17亿元、2023年度 13.9亿元 、2024年度 14.87亿元、2025年度(含中期分红)16.7亿元,谢谢。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300030295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0113","BK0196","BK0096","LU1820825898.SGD","BK0236","LU0979878070.USD","300015","BK0200","LU1242518931.SGD","BK0028","BK0077","LU1146622755.USD","LU1242518857.USD","BK0012","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640993138","title":"爱尔眼科:视网膜色素变性目前尚无法治愈","url":"https://stock-news.laohu8.com/highlight/detail?id=2640993138","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640993138?lang=zh_cn&edition=full","pubTime":"2026-06-02 08:38","pubTimestamp":1780360690,"startTime":"0","endTime":"0","summary":"证券之星消息,爱尔眼科(300015)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司在治疗视网膜色素性变上有哪些新的成果,是否有治疗成功案例,谢谢!爱尔眼科回复:谢谢关注!视网膜色素变性是复杂的遗传性疾病,目前尚无法治愈,但可通过及时的干预和规范的治疗延缓病情进展,改善生活质量。公司拥有多位专家,患者可预约看诊。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200008161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0028","LU0979878070.USD","300015","BK0200","BK0236","BK0113","LU1146622755.USD","BK0114","LU1242518931.SGD","LU1820825898.SGD","BK0012","BK0196","BK0096","LU1242518857.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640932035","title":"爱尔眼科:赴港上市是公司全球化布局的重要一步","url":"https://stock-news.laohu8.com/highlight/detail?id=2640932035","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640932035?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:51","pubTimestamp":1780303880,"startTime":"0","endTime":"0","summary":"证券之星消息,爱尔眼科06月01日在投资者关系平台上答复投资者关心的问题。其次,股价不断创历史新低,这节骨眼上更不适合赴港上市吧?希望公司顶层做出有效市值管理,让投资者更有信心。赴港上市是公司全球化布局的重要一步,通过海内外双向管理赋能,共享眼科智慧,提升内在价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100024902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1146622755.USD","BK0236","BK0188","BK0196","BK0114","BK0096","LU1242518857.USD","LU1820825898.SGD","LU0979878070.USD","300015","BK0200","LU1242518931.SGD","BK0113","BK0028","BK0012","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638665505","title":"爱尔眼科冲刺“A+H”,海外并购能否续上增长故事","url":"https://stock-news.laohu8.com/highlight/detail?id=2638665505","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638665505?lang=zh_cn&edition=full","pubTime":"2026-05-28 16:19","pubTimestamp":1779956376,"startTime":"0","endTime":"0","summary":"民营眼科龙头爱尔眼科,正在向“A+H”迈出关键一步。\n5月27日,爱尔眼科向港交所递交招股书,拟在港...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e7a4338b1034ad785d5025385d8625c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3773342","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0236","BK0114","BK0077","BK0200","LU1820825898.SGD","BK0012","LU0979878070.USD","BK0028","LU1242518857.USD","LU1242518931.SGD","300015","BK0113","BK0196","BK0188","BK0096","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638689493","title":"【新股IPO】爱尔眼科医院向港交所主板递交上市申请书 拟实现A+H上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2638689493","media":"金吾财讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638689493?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:39","pubTimestamp":1779892782,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所5月27日文件,爱尔眼科医院集团股份有限公司向港交所主板递交上市申请书,拟实现A+H上市,独家保荐人为华泰国际。公司已于2009年10月30日登陆深交所创业板。公司是全球最大眼科医疗服务集团,截至2025年末运营842家医疗机构,横跨三大洲,门诊量、手术量等多项核心指标位居全球首位,拥有超7500名眼科医生及千万级临床数据库。股权方面,陈邦及爱尔投资为公司控股股东,合计持有公司约49.82%股份,控制约49.99%投票权。","market":"nz","thumbnail":"https://static.szfiu.com/news/20220324/NjMyZjUxNTAyODM5OTc0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/NjMyZjUxNTAyODM5OTc0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1982349","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK0188","BK0236","BK0114","BK0028","IPOS","BK0096","LU1242518857.USD","BK0012","LU1242518931.SGD","LU1146622755.USD","300015","BK0077","BK0113","LU1820825898.SGD","LU0979878070.USD","HEXmain","BK0200"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781217532108,"stockEarnings":[{"period":"1week","weight":-0.0106},{"period":"1month","weight":-0.2036},{"period":"3month","weight":-0.1722},{"period":"6month","weight":-0.2379},{"period":"1year","weight":-0.3177},{"period":"ytd","weight":-0.2289}],"compareEarnings":[{"period":"1week","weight":-0.0174},{"period":"1month","weight":-0.054},{"period":"3month","weight":-0.0265},{"period":"6month","weight":0.0251},{"period":"1year","weight":0.1719},{"period":"ytd","weight":0.0046}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"爱尔眼科医院集团股份有限公司","boardCode":"AI0083","boardName":"卫生","stockholders":"344196人(较上一季度增加1.85%)","perCapita":"23112股","listingDate":"2009-10-30","address":"湖南省长沙市天心区芙蓉南路一段188号爱尔大厦","registeredCapital":"932539万元","survey":" 爱尔眼科医院集团股份有限公司的主营业务是各类眼科疾病诊疗、手术服务与医学验光配镜服务。公司的主要产品是屈光项目、白内障项目、眼前段项目、眼后段项目、视光服务项目。集团数字化多项成果获得行业及主管部门的高度认可。报告期内,“爱尔慢性眼病智能筛查一体化解决方案”获得全国人工智能应用创新大赛创新应用组二等奖;爱尔眼科“高真实感个性化眼科数字人底座开发与应用”项目成功入选湖南省“数字新基建”100个标志性项目名单;“爱尔眼科数字人及AierGPT”项目在第八届众智科学与工程国际会议(ICCSE2025)联合第十届人工智能与乐龄科技国际会议(ICAA2025)上荣获大会“最佳演示奖(BestDemoAward)”。同时,集团获湖南省发改委认定为“数字眼科湖南省工程研究中心”;主办中华医学会眼科学术大会眼科人工智能专题会,发布《爱尔眼科AI战略白皮书》,行业影响力显著提升。","listedPrice":28},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"爱尔眼科(300015)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供爱尔眼科(300015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"爱尔眼科,300015,爱尔眼科股票,爱尔眼科股票老虎,爱尔眼科股票老虎国际,爱尔眼科行情,爱尔眼科股票行情,爱尔眼科股价,爱尔眼科股市,爱尔眼科股票价格,爱尔眼科股票交易,爱尔眼科股票购买,爱尔眼科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"爱尔眼科(300015)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供爱尔眼科(300015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}